Navigation Links
SPRI Clinical Trials Now Enrolling Patients for Study of New Treatment for Depression
Date:10/15/2007

Patient Recruitment Starting Now -- For More Information, Call 888-345-7774

or Visit Our Website at http://www.spristudy.com

NEW YORK, Oct. 15 /PRNewswire/ -- SPRI Clinical Trials announced today that it is now screening patients for enrollment in the parAGOn Clinical Trial Program, which will start with two Phase III studies to evaluate the efficacy, safety and tolerability of agomelatine, a novel, investigational, once-daily medication for the treatment of Major Depressive Disorder (MDD). The 8-week, randomized, placebo-controlled studies are sponsored by Novartis Pharmaceuticals Corporation, and each of the two Phase III studies will include 490 patients from approximately 50 centers.

This investigational new drug targets both melatonin receptors and serotonin (5-HT2c) receptors.

The parAGOn Clinical Trial Program is open to patients between the ages of 18 and 70 who are experiencing MDD and meet other eligibility criteria. Eligible patients will be equally randomized to receive either treatment with agomelatine 25 mg, agomelatine 50 mg or placebo once daily for 8 weeks. Patients who complete the eight-week double-blind treatment phase may also participate in a 52-week open-label extension of the study.

MDD is the most common mood disorder, affecting approximately 15 million American adults, according to the National Alliance on Mental Illness. Common symptoms include: depressed mood, loss of interest in daily activities, poor concentration, weight loss (or gain), decrease of appetite, sleep disturbance, feelings of worthlessness and /or of guilt, and suicidal ideation. Episodes of depression may be chronic and recurrent, according to the National Institute of Mental Health.

Contact Dr. Nick Vatakis at 888-345-7774 for more information about the ParAGOn Clinical Trial Program.


'/>"/>
SOURCE SPRI Clinical Trials
Copyright©2007 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Genetic Analysis Systems Enter the Clinical Mainstream
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
4. Sygnis Pharma AG announces date for presentation of clinical results
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
9. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... 2017 This report on the opioid induced ... of the global market. Large number of chronic pain ... constipation is a major side effect of consumption of ... targeted therapy has been prescribed to treat opioid induced ... medicines, and growing awareness about the therapy are the ...
(Date:1/19/2017)... -- Accuray Incorporated (Nasdaq: ARAY ) announced ... set the bar for excellence in customer satisfaction. The ... rating among radiation treatment delivery systems in the U.S., ... Briefing™. The most recent ratings trend also shows Accuray ... for 11 of the past 12 quarters. ...
(Date:1/19/2017)... Shire plc (LSE: SHP, NASDAQ: ... and Drug Administration (FDA) has acknowledged receipt of the ... for SHP465, a long-acting, triple-bead, mixed amphetamine salts formulation. ... for Attention-Deficit/Hyperactivity Disorder (ADHD). The FDA is expected to ... the designated Prescription Drug User Fee Act (PDUFA) action ...
Breaking Medicine Technology:
(Date:1/20/2017)... ... , ... “The Land of More and More”: a brilliant story for ... shares the simple and achievable answer. “The Land of More and More” is the ... Church in Angola, Indiana where he works with the children’s ministry department. , ...
(Date:1/19/2017)... ... ... Next week after January 20th, the fear for many is that the ... needs of over 30 million. Many interviews with Dr. Carol Francis at the Los ... were suppose to prioritize. Interviews provided below. , Among those present was ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... innovators, engineers, and scientists from around the world, announces the launch of its ... quick and easy portal to research breakthroughs and trending news, vital information on ...
(Date:1/19/2017)... Park City, Utah (PRWEB) , ... January 19, ... ... Sundance Film Festival in a medical capacity this year. Drs. Alexander Paziotopoulos, Andrew ... Lounge to provide a condensed version of the clinic’s leading recovery program. ...
(Date:1/19/2017)... , ... January 19, 2017 , ... ... Conductor CTMS, which provides a modern CTMS workflow designed to seamlessly integrate and ... has been condensed to a single page, maximizing usability and improving efficiency significantly ...
Breaking Medicine News(10 mins):